# Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer

> **NCT00005096** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 19 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00005096
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-12
- **Primary completion:** 2002-06
- **Final completion:** 2002-06
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2017-07-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005096, "Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00005096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*